J-code: Drugs administered other than oral method; chemotherapy drugs Drugs administered other than oral method; chemotherapy drugs
1,255 codes
Billing context
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| J9313 | Injection, moxetumomab pasudotox-tdfk, 0.01 mg | — | Oct 1, 2019 | Active |
| J9314 | Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg | $10.986per 10 MG | Jan 1, 2023 | Active |
| J9315 | Injection, romidepsin, 1 mg | — | Jan 1, 2011 | Ended Sep 30, 2021 |
| J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | $59.491per 10 MG | Jan 1, 2021 | Active |
| J9317 | Injection, sacituzumab govitecan-hziy, 2.5 mg | $37.536per 2.5 MG | Jan 1, 2021 | Active |
| J9318 | Injection, romidepsin, non-lyophilized, 0.1 mg | $32.864per 0.1 MG | Oct 1, 2021 | Active |
| J9319 | Injection, romidepsin, lyophilized, 0.1 mg | $32.343per 0.1 MG | Oct 1, 2021 | Active |
| J9320 | Injection, streptozocin, 1 gram | — | Jan 1, 1986 | Active |
| J9321 | Injection, epcoritamab-bysp, 0.16 mg | $57.975per 0.16 MG | Jan 1, 2024 | Active |
| J9322 | Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg | — | Jul 1, 2023 | Active |
| J9323 | Injection, pemetrexed ditromethamine, 10 mg | — | Jul 1, 2023 | Active |
| J9324 | Injection, pemetrexed (pemrydi rtu), 10 mg | $63.580per 10 MG | Jan 1, 2024 | Active |
| J9325 | Injection, talimogene laherparepvec, per 1 million plaque forming units | $77.657per 1 million PFU | Jan 1, 2017 | Active |
| J9326 | Injection, telisotuzumab vedotin-tllv, 1 mg | $145.946per 1 MG | Jan 1, 2026 | Active |
| J9328 | Injection, temozolomide, 1 mg | $10.410per 1 MG | Jan 1, 2010 | Active |
| J9329 | Injection, tislelizumab-jsgr, 1mg | $58.086per 1 MG | Oct 1, 2024 | Active |
| J9330 | Injection, temsirolimus, 1 mg | $27.707per 1 MG | Jan 1, 2009 | Active |
| J9331 | Injection, sirolimus protein-bound particles, 1 mg | $91.030per 1 MG | Jul 1, 2022 | Active |
| J9332 | Injection, efgartigimod alfa-fcab, 2mg | $32.347per 2 MG | Jul 1, 2022 | Active |
| J9333 | Injection, rozanolixizumab-noli, 1 mg | $23.626per 1 MG | Jan 1, 2024 | Active |
| J9334 | Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc | $33.590per 2 MG | Jan 1, 2024 | Active |
| J9340 | Injection, thiotepa, 15 mg | — | Jan 1, 1984 | Ended Jun 30, 2025 |
| J9341 | Injection, thiotepa (tepylute), 1 mg | $37.841per 1 MG | Jul 1, 2025 | Active |
| J9342 | Injection, thiotepa, not otherwise specified, 1 mgNOC / NOS | $5.871per 1 MG | Jul 1, 2025 | Active |
| J9345 | Injection, retifanlimab-dlwr, 1 mg | $30.932per 1 MG | Oct 1, 2023 | Active |
| J9347 | Injection, tremelimumab-actl, 1 mg | $146.991per 1 MG | Jul 1, 2023 | Active |
| J9348 | Injection, naxitamab-gqgk, 1 mg | $685.988per 1 MG | Jul 1, 2021 | Active |
| J9349 | Injection, tafasitamab-cxix, 2 mg | $14.428per 2 MG | Apr 1, 2021 | Active |
| J9350 | Injection, mosunetuzumab-axgb, 1 mg | $676.484per 1 MG | Jul 1, 2023 | Active |
| J9351 | Injection, topotecan, 0.1 mg | $2.067per 0.1 MG | Jan 1, 2011 | Active |
| J9352 | Injection, trabectedin, 0.1 mg | — | Jan 1, 2017 | Ended Sep 30, 2026 |
| J9353 | Injection, margetuximab-cmkb, 5 mg | $56.046per 5 MG | Jul 1, 2021 | Active |
| J9354 | Injection, ado-trastuzumab emtansine, 1 mg | $43.860per 1 MG | Jan 1, 2014 | Active |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | $68.871per 10 MG | Jan 1, 2000 | Active |
| J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk | $58.038per 10 MG | Jul 1, 2019 | Active |
| J9357 | Injection, valrubicin, intravesical, 200 mg | $1,230.664per 200 MG | Jan 1, 2000 | Active |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | $32.653per 1 MG | Jul 1, 2020 | Active |
| J9359 | Injection, loncastuximab tesirine-lpyl, 0.075 mg | $226.565per 0.075 MG | Apr 1, 2022 | Active |
| J9360 | Injection, vinblastine sulfate, 1 mg | $5.754per 1 MG | Jan 1, 1986 | Active |
| J9361 | Injection, efbemalenograstim alfa-vuxw, 0.5 mg | $121.429per 0.5 MG | Jul 1, 2024 | Active |
| J9362 | Injection, trabectedin, 0.01 mg | $41.844per 0.01 MG | Oct 1, 2026 | Active |
| J9370 | Vincristine sulfate, 1 mg | $9.426per 1 MG | Jan 1, 1986 | Active |
| J9371 | Injection, vincristine sulfate liposome, 1 mg | — | Jan 1, 2014 | Ended Jun 30, 2024 |
| J9376 | Injection, pozelimab-bbfg, 1 mg | — | Apr 1, 2024 | Active |
| J9380 | Injection, teclistamab-cqyv, 0.5 mg | $35.818per 0.5 MG | Jul 1, 2023 | Active |
| J9381 | Injection, teplizumab-mzwv, 5 mcg | $39.274per 5 MCG | Jul 1, 2023 | Active |
| J9382 | Injection, zenocutuzumab-zbco, 1 mg | $33.869per 1 MG | Jul 1, 2025 | Active |
| J9390 | Injection, vinorelbine tartrate, 10 mg | $4.148per 10 MG | Jan 1, 1996 | Active |
| J9393 | Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg | — | Jan 1, 2023 | Active |
| J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | — | Jan 1, 2023 | Active |
| J9395 | Injection, fulvestrant, 25 mg | $5.021per 25 MG | Jan 1, 2004 | Active |
| J9400 | Injection, ziv-aflibercept, 1 mg | $9.702per 1 MG | Jan 1, 2014 | Active |
| J9600 | Injection, porfimer sodium, 75 mg | — | Jan 1, 1998 | Active |
| J9601 | Injection, linvoseltamab-gcpt, 1 mg | $99.134per 1 MG | Apr 1, 2026 | Active |
| J9999 | Not otherwise classified, antineoplastic drugsNOC / NOS | — | Jan 1, 1986 | Active |